This information collection request
collects information from an adult sample of individuals who
self-identify as having rheumatoid arthritis or overactive bladder
regarding their perceptions of the important safety information and
brief summary in direct-to-consumer prescription drug print
advertising. Additionally, we will collect eye-tracking data to
observe participants’ gaze maps while reading the information.
Using an in-person interview methodology, we plan to conduct two
60-minute pilots with a total of 40 adults and two 60-minute
studies with a total of 400 adults.
Ila Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.